Parkside Financial Bank & Trust Sells 66 Shares of Zoetis Inc. (NYSE:ZTS)

Parkside Financial Bank & Trust lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,873 shares of the company’s stock after selling 66 shares during the period. Parkside Financial Bank & Trust’s holdings in Zoetis were worth $305,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. State Street Corp raised its stake in shares of Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after purchasing an additional 95,856 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Zoetis by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after purchasing an additional 185,364 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Zoetis by 8.5% during the 4th quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company’s stock worth $906,202,000 after purchasing an additional 433,429 shares in the last quarter. Mizuho Securities USA LLC raised its stake in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Zoetis by 5.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after acquiring an additional 194,542 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Piper Sandler increased their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, StockNews.com cut Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Stock Up 1.6 %

ZTS stock opened at $167.58 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock has a market capitalization of $75.04 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90. The business’s fifty day moving average price is $166.30 and its two-hundred day moving average price is $177.38. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.